title: Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.
abstract: OBJECTIVE
  To perform a meta-analysis to derive a more precise estimation of imatinib treatment for different genotypes of gastrointestinal stromal tumors (GIST).
  
  
  METHODS
  Studies were identified by searching PubMed and Embase. Inclusive criteria were patients with exon 9-mutant, exon 11-mutant or wide type (WT) GIST, receiving chemotherapy of imatinib for clinical trial, and efficacy evaluation was cumulative response (CR) including complete response and partial response. The odds ratios (OR) for CR in stem cell factor receptor (KIT) mutation patients vs WT genotype patients, KIT exon 11-mutant genotype patients vs KIT exon 9-mutant genotype patients and KIT exon 9-mutant genotype patients vs WT genotype patients were calculated with 95% confidence interval (CI) for each study as an estimation of the efficacy of imatinib.
  
  
  RESULTS
  Five studies including 927 patients were involved in this meta-analysis. The overall OR (KIT group vs WT group) was 3.34 (95% CI: 2.30-4.86, P < 0.00001, P(heterogeneity) = 0.04). The overall OR in KIT exon 11 group vs KIT exon 9 group was 3.29 (95% CI: 2.17-5.00, P < 0.00001, P(heterogeneity) = 0.33). The overall OR in KIT exon 9 group vs WT group was 1.23 (95% CI: 0.73-2.10, P = 0.44, P(heterogeneity) = 0.42).
  
  
  CONCLUSIONS
  Most patients with different genotypes of GIST and KIT exon 11-mutant will benefit from the individualized treatment of imatinib.
authors.affiliation: Department of Gastrointestinal Surgery, Subei People's Hospital of Jiangsu Province, Yangzhou 225001, Jiangsu Province, China. chen86ky@126.com
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
authors.forename: Liang
authors.initials: L
authors.lastname: Zong
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.forename: Lei
authors.initials: L
authors.lastname: Shi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005091:Exons / Q000235:genetics; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics; D005838:Genotype; D006801:Humans; D000068877:Imatinib Mesylate; D009154:Mutation / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit
references.citation: Arch Surg. 2001 Apr;136(4):383-9
references.pmid: 11296107
references.citation: Curr Treat Options Oncol. 2002 Dec;3(6):489-96
references.pmid: 12392638
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5360-7
references.pmid: 18955451
references.citation: J Clin Oncol. 2004 Sep 15;22(18):3813-25
references.pmid: 15365079
references.citation: Hum Pathol. 2002 May;33(5):466-77
references.pmid: 12094371
references.citation: N Engl J Med. 2002 Aug 15;347(7):472-80
references.pmid: 12181401
references.citation: Science. 1998 Jan 23;279(5350):577-80
references.pmid: 9438854
references.citation: Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
references.pmid: 15451219
references.citation: Eur J Cancer. 2006 May;42(8):1093-103
references.pmid: 16624552
references.citation: Cancer Res. 2004 Sep 1;64(17):5913-9
references.pmid: 15342366
references.citation: J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97
references.pmid: 17458563
references.citation: Eur J Surg Oncol. 2008 May;34(5):563-8
references.pmid: 17532173
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4342-9
references.pmid: 14645423
references.citation: Ann Surg Oncol. 2007 Mar;14(3):1123-8
references.pmid: 17195905
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5357-64
references.pmid: 15928335
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1743-9
references.pmid: 16551858
references.citation: Science. 2003 Jan 31;299(5607):708-10
references.pmid: 12522257
references.citation: J Clin Oncol. 2000 Sep 15;18(18):3211-20
references.pmid: 10986053
references.citation: J Clin Oncol. 2008 Feb 1;26(4):620-5
references.pmid: 18235121
references.citation: Gastroenterology. 2003 Sep;125(3):660-7
references.pmid: 12949711
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Clin Oncol. 2008 Feb 1;26(4):626-32
references.pmid: 18235122
references.citation: Gastroenterology. 2006 May;130(6):1573-81
references.pmid: 16697720
references.citation: Br J Surg. 2003 Mar;90(3):332-9
references.pmid: 12594669